FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894037505> ?p ?o ?g. }

• W2894037505 endingPage "2675" @default.
• W2894037505 startingPage "2665" @default.
• W2894037505 abstract "Abstract Microtubule-targeting agents (MTA) have been investigated for many years as payloads for antibody–drug conjugates (ADC). In many cases, these ADCs have shown limited benefits due to lack of efficacy or significant toxicity, which has spurred continued investigation into novel MTA payloads for next-generation ADCs. In this study, we have developed ADCs using the MTA eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, as a payload. Eribulin ADCs demonstrated in vitro potency and specificity using various linkers and two different conjugation approaches. MORAb-202 is an investigational agent that consists of the humanized anti-human folate receptor alpha (FRA) antibody farletuzumab conjugated via reduced interchain disulfide bonds to maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl-eribulin at a drug-to-antibody ratio of 4.0. MORAb-202 displayed preferable biophysical properties and broad potency across a number of FRA-positive tumor cell lines as well as demonstrated improved specificity in vitro compared with farletuzumab conjugated with a number of other MTA payloads, including MMAE, MMAF, and the reducible maytansine linker-payload sulfo-SPDB-DM4. A single-dose administration of MORAb-202 in FRA-positive human tumor cell line xenograft and patient-derived tumor xenograft models elicited a robust and durable antitumor response. These data support further investigation of MORAb-202 as a potential new treatment modality for FRA-positive cancers, using the novel MTA eribulin as a payload." @default.
• W2894037505 created "2018-10-05" @default.
• W2894037505 creator A5009791851 @default.
• W2894037505 creator A5012677271 @default.
• W2894037505 creator A5017855628 @default.
• W2894037505 creator A5018941543 @default.
• W2894037505 creator A5019818789 @default.
• W2894037505 creator A5036707660 @default.
• W2894037505 creator A5042776055 @default.
• W2894037505 creator A5043912537 @default.
• W2894037505 creator A5048740935 @default.
• W2894037505 creator A5050738431 @default.
• W2894037505 creator A5057972233 @default.
• W2894037505 creator A5063987949 @default.
• W2894037505 creator A5068678429 @default.
• W2894037505 creator A5070054905 @default.
• W2894037505 creator A5075178778 @default.
• W2894037505 creator A5083015075 @default.
• W2894037505 date "2018-12-01" @default.
• W2894037505 modified "2023-10-10" @default.
• W2894037505 title "MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity" @default.
• W2894037505 cites W1521126454 @default.
• W2894037505 cites W1524815067 @default.
• W2894037505 cites W1675907882 @default.
• W2894037505 cites W1973108158 @default.
• W2894037505 cites W1983225377 @default.
• W2894037505 cites W1988263368 @default.
• W2894037505 cites W1993012864 @default.
• W2894037505 cites W1996337127 @default.
• W2894037505 cites W2010363872 @default.
• W2894037505 cites W2010442254 @default.
• W2894037505 cites W2013891780 @default.
• W2894037505 cites W2017596768 @default.
• W2894037505 cites W2024132257 @default.
• W2894037505 cites W2032603070 @default.
• W2894037505 cites W2036022736 @default.
• W2894037505 cites W2053558130 @default.
• W2894037505 cites W2062486240 @default.
• W2894037505 cites W2083035675 @default.
• W2894037505 cites W2090057677 @default.
• W2894037505 cites W2093855538 @default.
• W2894037505 cites W2105183657 @default.
• W2894037505 cites W2107006180 @default.
• W2894037505 cites W2107569143 @default.
• W2894037505 cites W2127152525 @default.
• W2894037505 cites W2138941973 @default.
• W2894037505 cites W2149274493 @default.
• W2894037505 cites W2150244588 @default.
• W2894037505 cites W2150869832 @default.
• W2894037505 cites W2157576385 @default.
• W2894037505 cites W2159967578 @default.
• W2894037505 cites W2167077543 @default.
• W2894037505 cites W2171368669 @default.
• W2894037505 cites W2179141110 @default.
• W2894037505 cites W2237971187 @default.
• W2894037505 cites W2262783978 @default.
• W2894037505 cites W2307372011 @default.
• W2894037505 cites W2313984291 @default.
• W2894037505 cites W2341138808 @default.
• W2894037505 cites W2346198182 @default.
• W2894037505 cites W2420436228 @default.
• W2894037505 cites W2586608125 @default.
• W2894037505 cites W2597045666 @default.
• W2894037505 cites W2604560583 @default.
• W2894037505 cites W2605812599 @default.
• W2894037505 cites W2608845032 @default.
• W2894037505 cites W2735955876 @default.
• W2894037505 cites W2750012732 @default.
• W2894037505 cites W4239380575 @default.
• W2894037505 cites W4244008531 @default.
• W2894037505 cites W4297742529 @default.
• W2894037505 doi "https://doi.org/10.1158/1535-7163.mct-17-1215" @default.
• W2894037505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262588" @default.
• W2894037505 hasPublicationYear "2018" @default.
• W2894037505 type Work @default.
• W2894037505 sameAs 2894037505 @default.
• W2894037505 citedByCount "49" @default.
• W2894037505 countsByYear W28940375052019 @default.
• W2894037505 countsByYear W28940375052020 @default.
• W2894037505 countsByYear W28940375052021 @default.
• W2894037505 countsByYear W28940375052022 @default.
• W2894037505 countsByYear W28940375052023 @default.
• W2894037505 crossrefType "journal-article" @default.
• W2894037505 hasAuthorship W2894037505A5009791851 @default.
• W2894037505 hasAuthorship W2894037505A5012677271 @default.
• W2894037505 hasAuthorship W2894037505A5017855628 @default.
• W2894037505 hasAuthorship W2894037505A5018941543 @default.
• W2894037505 hasAuthorship W2894037505A5019818789 @default.
• W2894037505 hasAuthorship W2894037505A5036707660 @default.
• W2894037505 hasAuthorship W2894037505A5042776055 @default.
• W2894037505 hasAuthorship W2894037505A5043912537 @default.
• W2894037505 hasAuthorship W2894037505A5048740935 @default.
• W2894037505 hasAuthorship W2894037505A5050738431 @default.
• W2894037505 hasAuthorship W2894037505A5057972233 @default.
• W2894037505 hasAuthorship W2894037505A5063987949 @default.
• W2894037505 hasAuthorship W2894037505A5068678429 @default.
• W2894037505 hasAuthorship W2894037505A5070054905 @default.
• W2894037505 hasAuthorship W2894037505A5075178778 @default.

• next